Welcome to our dedicated page for PDS Biotechnology Corporation news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on PDS Biotechnology Corporation stock.
PDS Biotechnology Corporation (Nasdaq: PDSB) is a clinical stage biopharmaceutical company focused on developing next-generation immunotherapies for cancer and infectious diseases. The company's proprietary Versamune® platform leverages synthetic and biodegradable lipids to form nanoparticles that are readily taken up by the immune system. These nanoparticles are designed to activate and direct the immune system to target and eliminate disease-causing cells.
PDS Biotech's lead product candidates include PDS0101, targeting HPV-related cancers, and PDS01ADC, an IL-12 fused antibody drug conjugate. These candidates are part of the company's broader strategy to treat a range of cancers, including head and neck, prostate, breast, cervical, and anal cancers.
Recent achievements include the completion of a Phase 1 clinical trial for PDS0101 and ongoing Phase 2 trials demonstrating positive survival results and tumor shrinkage. The company is preparing to initiate a pivotal clinical trial in advanced head and neck cancers in 2024.
Financially, PDS Biotech reported a net loss of $10.8 million for Q3 2023, primarily due to increased R&D and administrative expenses. Despite this, the company remains focused on advancing its pipeline and has several key partnerships to support its research and development efforts.
PDS Biotechnology (Nasdaq: PDSB) has announced that an abstract presenting updated data from their VERSATILE-002 trial has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The trial evaluates the first-line treatment with Versamune® HPV (formerly PDS0101) in combination with KEYTRUDA® (pembrolizumab) for patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
The poster presentation, titled 'VERSATILE-002: Survival with First-Line Treatment with PDS0101 Therapeutic Vaccine and Pembrolizumab in HPV16-positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)', will be presented by Dr. Jared Weiss, Principal Investigator of the VERSATILE-002 clinical trial. The ESMO Congress 2024 is scheduled for September 13-17, 2024, in Barcelona, Spain.
PDS Biotechnology (Nasdaq: PDSB) has aligned with the FDA on the Phase 3 VERSATILE-003 trial for its Versamune® HPV immunotherapy in HPV16-positive first-line recurrent or metastatic head and neck cancer. The trial, set to begin in Q4 2024, will focus on the combination of Versamune® HPV and pembrolizumab, which has received Fast Track designation. The company presented data from VERSATILE-002 and proposed a triple combination therapy, which the FDA supported. However, to avoid delays, the FDA agreed to proceed with the 2-arm double combination trial. The updated VERSATILE-003 study will have overall survival as the primary endpoint, with revised statistical endpoints based on mature survival data.
PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company, has announced a conference call scheduled for August 1, 2024, at 8:00 a.m. ET to provide a clinical program update. The company, which focuses on enhancing immune system targeting of cancers and developing infectious disease vaccines, will offer multiple ways for interested parties to join the call:
1. Dial-in options: 1-877-704-4453 or 1-201-389-0920
2. Webcast registration available via provided link
3. Call Me™ feature available 15 minutes before the call
This update presents an opportunity for investors and stakeholders to gain insights into PDS Biotech's latest developments in immunotherapy and vaccine research.
PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company, has announced its participation in the BTIG Virtual Biotechnology Conference. The company's President and CEO, Frank Bedu-Addo, PhD, will engage in a fireside chat on Monday, August 5, 2024, at 10:00 a.m. ET.
PDS Biotech focuses on revolutionizing how the immune system targets and eliminates cancers, as well as developing vaccines for infectious diseases. Interested parties can arrange meetings with the PDS Biotech team through their BTIG representatives. After the event, a replay of the fireside chat will be accessible in the Investor Relations section of the company's website at www.pdsbiotech.com.
PDS Biotechnology provided a data update from its VERSATILE-002 Phase 2 clinical trial in head and neck cancer as of May 17, 2024. The trial focuses on the combination of Versamune® HPV and KEYTRUDA® in HPV16-positive HNSCC patients. Median Overall Survival (mOS) remains at 30 months, consistent with previous data. Out of 53 enrolled patients, 27 remain alive, 6 withdrew consent, 2 were lost to follow-up, and 18 have died. The lower limit of the 95% confidence interval is 19.7 months, while the upper limit is not yet estimable. Full data are expected in Q3 2024. PDS Biotech plans a three-arm Phase 3 trial to further evaluate treatment efficacy.
PDS Biotech (Nasdaq: PDSB) has released its Q1 2024 financial results and business updates. Key highlights include positive data from the Phase 2 VERSATILE-002 trial for HPV16-positive head and neck cancer, showing improved survival rates with Versamune® HPV and KEYTRUDA®. The company also announced a new two-part clinical trial strategy for Versamune® in combination with PDS01ADC and pembrolizumab. Financials show a net loss of $10.6 million, up from $9.7 million in Q1 2023, mainly due to increased R&D and interest expenses. Cash reserves stand at $66.6 million.
PDS Biotech's VERSATILE-002 Phase 2 clinical trial for first-line recurrent/metastatic HPV16-positive head and neck cancer met primary study endpoints with a 30-month median overall survival, impressive response rates, and a planned Phase 3 trial in 2024. The trial evaluated the combination of Versamune® HPV + KEYTRUDA® (pembrolizumab) and showed promising results. The Company also announced a two-part registrational trial focusing on a triple combination therapy.
PDS Biotechnology (Nasdaq: PDSB) will participate in two investor conferences in May 2024. The first is the Citizens JMP Life Sciences Conference on May 13 in New York, where the company will present and hold 1:1 meetings. The second event is the A.G.P.'s Virtual Healthcare Company Showcase on May 21, featuring a fireside chat with A.G.P.’s Jim Molloy and Scott Henry.
PDS Biotech, a late-stage immunotherapy company, will announce its first quarter 2024 financial results on May 15, 2024. They will also discuss positive data from their VERSATILE-002 Phase 2 clinical trial during a Key Opinion Leader Event on May 8, 2024.
PDS Biotechnology announced details of a virtual Key Opinion Leader (KOL) event focusing on updated Phase 2 trial results and unmet needs in advanced head and neck cancer. The event will discuss the positive data from the VERSATILE-002 trial and plans for a triple combination trial. Panel participants include renowned experts in the field.
FAQ
What is the current stock price of PDS Biotechnology Corporation (PDSB)?
What is the market cap of PDS Biotechnology Corporation (PDSB)?
What is PDS Biotechnology Corporation's main area of focus?
What is the Versamune® platform?
Which cancers are targeted by PDS Biotechnology's therapies?
What are the recent achievements of PDS Biotechnology?
How did PDS Biotechnology perform financially in Q3 2023?
What is PDS01ADC?
What upcoming events should investors watch?
What are the unique features of PDS Biotechnology's vaccines?
Where can investors find more information about PDS Biotechnology?